Most of the immunosuppressive therapy-associated excess lymphomas in IBD are due to a loss of control of Epstein-Barr virus (EBV) infection. Systemic EBV viral-load monitoring and preemptive treatments are extensively used in the posttransplant setting, but these methods have not yet been evaluated in IBD patients and cannot therefore be recommended in this context. However, the systemic EBV viral load should be measured in cases of unexplained fever, lymphadenopathy or hemophagocytic syndrome, in order to optimize the diagnostics of early EBV-related lymphoproliferations. The risk of hepatosplenic T cell lymphoma can, theoretically, be limited by avoiding prolonged combination therapy with thiopurines and anti-tumor necrosis factor (anti-TNF) beyond 2 years in young males. Young males seronegative for EBV are at risk for fatal forms of primary EBV infection, with postmononucleosis lymphoproliferation. This incidence could be limited by considering avoiding treatment with thiopurines in this subgroup of patients. There is a marked excess risk of nonmelanoma skin cancer in IBD patients currently or previously treated with thiopurines, which justifies lifelong sun protection and dermatological screening in these patients. The level of risk is still unclear for monotherapies with anti-TNF. An excess of human papilloma virus (HPV)-related uterine cervix dysplasia and cancer has been reported in various populations of women with IBD, but the proper role of immunosuppressive therapy remains to be quantified. However, yearly screening for uterine cervix abnormalities is recommended for all female IBD patients, along with HPV vaccination in young girls.

Keywords:
Cancers, Lymphoma, Immunosuppressive therapy, Posttransplant setting
1.
Jemal A, Clegg LX, Ward E, et al: Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 2004;101:3–27.
2.
Sokol H, Beaugerie L: Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009;58:1427–1436.
3.
Beaugerie L, Brousse N, Bouvier AM, et al: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617–1625.
4.
Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121–1125.
5.
Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874–881.
6.
Morris MC, Edmunds WJ, Hesketh LM, et al: Sero-epidemiological patterns of Epstein-Barr and herpes simplex (HSV-1 and HSV-2) viruses in England and Wales. J Med Virol 2002;67:522–527.
7.
Stevens SJ, Verschuuren EA, Pronk I, et al: Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001;97:1165–1171.
8.
Darenkov IA, Marcarelli MA, Basadonna GP, et al: Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997;64:848–852.
9.
Comoli P, Basso S, Zecca M, et al: Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007;7:1648–1655.
10.
Heslop HE, Slobod KS, Pule MA, et al: Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115:925–935.
11.
Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A: Preemptive diagnosis and treatment of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006;37:539–546.
12.
Beaugerie L, Pardi DS: Patients with drug-induced microscopic colitis should not be included in controlled trials assessing the efficacy of anti-inflammatory drugs in microscopic colitis. Gastroenterology 2009;137:1535–1536.
13.
Reijasse D, Le Pendeven C, Cosnes J, et al: Epstein-Barr virus viral load in Crohn’s disease: effect of immunosuppressive therapy. Inflamm Bowel Dis 2004;10:85–90.
14.
Serrate C, Silva-Moreno M, Dartigues P, et al: Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn’s disease. Inflamm Bowel Dis 2009;15:1449–1451.
15.
Kotlyar DS, Osterman MT, Diamond RH, et al: A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36–41.
16.
Posthuma EF, Westendorp RG, van der Sluys Veer A, Kluin-Nelemans JC, Kluin PM, Lamers CB: Fatal infectious mononucleosis: a severe complication in the treatment of Crohn’s disease with azathioprine. Gut 1995;36:311–313.
17.
Pachlopnik Schmid J, Canioni D, Moshous D, et al: Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011;117:1522–1529.
18.
Rahier JF, Ben-Horin S, Chowers Y, et al: European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in IBD. J Crohns Colitis 2009;3:47–91.
19.
O’Donovan P, Perrett CM, Zhang X, et al: Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309:1871–1874.
20.
Perrett CM, Walker SL, O’Donovan P, et al: Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008;159:198–204.
21.
Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD: Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010;8:268–274.
22.
Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al: Increased risk for non-melanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621–1628.
23.
Singh H, Nugent Z, Demers AA, Bernstein CN: Increased risk of non-melanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011;141:1612–1620.
24.
Zanetti R, Rosso S, Martinez C, et al: The multicentre south European study ‘Helios’. I. Skin characteristics and sunburns in basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996;73:1440–1446.
25.
Kane S, Khatibi B, Reddy D: Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103:631–636.
26.
Bhatia J, Bratcher J, Korelitz B, et al: Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 2006;12:6167–6171.
27.
Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN: Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 2009;136:451–458.
28.
Kane S: Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1158–1160.
29.
Gutierrez-Dalmau A, Campistol JM: Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007;67:1167–1198.
30.
Conraads VM, Denollet J, Vorlat A, Moulijn AC, Vrints CJ: Screening for solid organ malignancies prior to heart transplantation. Transplantation 2001;71:1481–1483.
31.
Penn I: The effect of immunosuppression on pre-existing cancers. Transplantation 1993;55:742–747.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.